TYO:4523

Eisai . Stock Predictions

Healthcare > Drug Manufacturers - Specialty & Generic

Buy 4523

*Your capital is at risk

JP¥4,949.00

+171.00 (+3.58%)

At Close: Aug 10, 2026

Currently predicting for Wed, 12 Aug 2026

4523.T Live board

Community Bull/Bear

Target Next close

Join the 4523.T prediction battle

Create a free account to see the full board, submit your call, compare with other predictors, and build a public record.

Create free account Log in

4523.T Prediction Chart

Unlock the prediction chart

Registered users can inspect target prices, community averages, and how calls develop across recent sessions.

Create free account Log in

Forecast Desk

3-Month Forecasts For 4523.T

Forecasts map a 66-session price path from approved predictors. Log in or create a free account to view forecasts and request one for this ticker.

Create free account Log in to view forecasts

4523.T Predictions History

Predictor	Target Session	Target Price	Accuracy
Community predictor	Next session	JPY target	Record locked
Ranked predictor	Previous session	Bullish/Bearish	Score locked

See the prediction record

Create free account Log in

Forecast Desk

Request A 3-Month Forecast

Price path
Approved predictor
3-month horizon

Create Free Account Log In To View Forecasts

ABOUT EISAI CO.,LTD.

Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomni...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
GPOR $158.45	6.03%	Aug 06
FCX $62.63	12.61%	Jul 31
BIIB $202.19	2.44%	Jul 24
TSCO $30.32	14.18%	Jul 23
S SW $43.71	8.88%	Jul 23

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by